ESR1 and breast carcinoma: Third, approximately 40% to 50% of ERα-positive breast cancers treated with conventional hormone therapies such as tamoxifen or aromatase inhibitors (AIs) will recur with drug-resistant disease, and AR-directed therapies may still be efficacious in this patient population.